CompletedNot Applicable

Erythropoiesis Stimulating Agents for Anemia Management in Egyptian Hemodialysis Patients

Egypt127 participantsStarted 2021-01-01

Plain-language summary

This observational study aims to compare long-acting darbepoetin alpha versus short-acting epoetin alpha erythropoietin-stimulating agents in Egyptian hemodialysis patients. The main questions aim to answer are: * What are the effectiveness and safety of long- acting versus short-acting erythropoietin-stimulating agents in Egyptian hemodialysis patients? * What is the cost-effectiveness of long- acting versus short-acting erythropoietin-stimulating agents in Egyptian hemodialysis patients? Participants will be divided into 2 groups; epoetin alfa (short-acting ESA), Eprex group, and darbepoetin alfa (long-acting ESA), Aranesp group for six month study period.

Who can participate

Age range18 Years – 75 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Patients who have been stable and undergoing hemodialysis three times per week for at least three months * Age must be 18 or older * Patients who had been receiving a single form of ESA treatment for at least three months before the study's launch. Exclusion Criteria: * altered the type of ESA therapy; 2) underwent significant surgery; or (3) received RBC transfusions * failed to adhere to dialysis therapy, as shown by missing more than two appointments each month. * have COVID-19 infection. * had cancer. * underwent a kidney transplant * were pregnant or nursing mothers * were not followed up for the full six-month research period.

What they're measuring

Percentage of patients reaching the target Hemoglobin in each group.

Timeframe: baseline to six months

Trial details

NCT IDNCT05699109

SponsorHelwan University

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2021-09-30